关键词：骨关节炎疼痛药物市场；适度增长；改进；需求；可用性
摘 要：The global osteoarthritis pain drugs market is expected to witness a moderate growth rate and post a CAGR of 8.38% during the period 2015-2020. In 2015, the Americas dominated the market, with major contribution from the US. The Americas was followed by EMEA and APAC. There is a vast opportunity for vendors in the market to expand into APAC due to the rising demand and availability of improved and advanced healthcare facilities in the region.
目 录：

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Assumptions

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

Key buying criteria

PART 05: Disease overview

Understanding osteoarthritis

Etiology and pathophysiology

Risk factors

Signs and symptoms

Diagnosis

Disease management

Surgical treatment

Epidemiology

Economic burden of osteoarthritis

PART 06: Pipeline portfolio

Information on pipeline candidates

Ampion

Tanezumab

Zilretta (FX006)

Fasinumab

IP 880

SoluMatrix Naproxen

ABT-981

AF-219

ASP7962

PART 07: Osteoarthritis pain drugs: Clinical trials

PART 08: Opportunities for research in osteoarthritis

Gaps between current research and possible research

issues

Challenges for vendors involved in osteoarthritis drug

development

PART 09: Market landscape

Market overview

Market size and forecast

Five forces analysis

PART 10: Market segmentation by drug class

NSAIDs

Opioids

Viscosupplements

Corticosteroids

Others

Global NSAIDs market

Global opioids market

Global viscosupplements market

Global corticosteroids market

PART 11: Market segmentation by ROA

Oral

Parenteral

Topical

PART 12: Market segmentation by dosage form

Solid

Liquid

Semi-solid

PART 13: Geographical segmentation

Osteoarthritis pain drugs market in Americas

Osteoarthritis pain drugs market in US

Osteoarthritis pain drugs market in EMEA

Osteoarthritis pain drugs market in APAC

PART 14: Market drivers

Significant unmet medical needs

Promising drug pipeline

Increase in prevalence of osteoarthritis and obesity

PART 15: Impact of drivers

PART 16: Market challenge

Preference for alternative therapies

Loss of patent exclusivity of branded therapies

Adverse effects of drugs

PART 17: Impact of drivers and challenges

PART 18: Market trends

Emergence of new treatments

Use of off-label drugs

Strategic alliances

PART 19: Vendor landscape

Competitive scenario

Abbott Laboratories

Johnson & Johnson

Novartis

Pfizer

Other prominent vendors

PART 20: Upcoming vendors with novel approaches

Ampio Pharmaceuticals

Flexion Therapeutics

Kitov Pharmaceuticals HRITIS PAIN DRUGS MARKET 2016-2020

PART 21: Appendix

List of abbreviations

PART 22: Explore Technavio